title: Consensus on precision medicine for metastatic cancers: a report from the MAP conference.
abstract: Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.
authors.affiliation: Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London UCL Hospitals and Cancer Institute, London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Swanton
authors.affiliation: Drug Development Unit, Gustave Roussy, Villejuif Department of Medical Oncology, INSERM Unit U981, Faculté de medicine Paris-Sud XI, Kremlin-Bicêtre, Villejuif, France.
authors.forename: J-C
authors.initials: JC
authors.lastname: Soria
authors.affiliation: Department of Oncology, University of Torino, Candiolo, Torino Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Bardelli
authors.affiliation: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, UK South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Liverpool, New South Wales, Australia West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow.
authors.forename: A
authors.initials: A
authors.lastname: Biankin
authors.affiliation: Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
authors.forename: C
authors.initials: C
authors.lastname: Caldas
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chandarlapaty
authors.affiliation: Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: de Koning
authors.affiliation: Clinical and Experimental Pharmacology, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
authors.forename: C
authors.initials: C
authors.lastname: Dive
authors.affiliation: Stabilité Génétique et Oncogenèse, Université Paris-Sud, Gustave-Roussy, Villejuif, France.
authors.forename: J
authors.initials: J
authors.lastname: Feunteun
authors.affiliation: Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
authors.forename: S-Y
authors.initials: SY
authors.lastname: Leung
authors.affiliation: Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
authors.forename: R
authors.initials: R
authors.lastname: Marais
authors.affiliation: McDonnell Genome Institute, Washington University School of Medicine, St Louis, USA.
authors.forename: E R
authors.initials: ER
authors.lastname: Mardis
authors.affiliation: Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London.
authors.forename: N
authors.initials: N
authors.lastname: McGranahan
authors.affiliation: Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham.
authors.forename: G
authors.initials: G
authors.lastname: Middleton
authors.affiliation: Cancer Immunology Unit, University College London Cancer Institute, University College London, London, UK.
authors.forename: S A
authors.initials: SA
authors.lastname: Quezada
authors.affiliation: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Rodón
authors.affiliation: Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge.
authors.forename: N
authors.initials: N
authors.lastname: Rosenfeld
authors.affiliation: Breast Cancer Translational Research Laboratory-BCTL (ULB 290), Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Sotiriou
authors.affiliation: Department of Medical Oncology, INSERM Unit U981, Faculté de medicine Paris-Sud XI, Kremlin-Bicêtre, Villejuif, France fandre@igr.fr fabrice.andre@igr.fr.
authors.forename: F
authors.initials: F
authors.lastname: André
mesh_terms: D023281:Genomics; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D057285:Precision Medicine; D040901:Proteomics
keywords: biomarkers; consensus; precision medicine